LDL Cholesterol
LDL cholesterol quantifies the cholesterol carried on low-density lipoprotein particles, which deposit lipids in arterial walls and drive atherosclerosis. It is the primary modifiable target for preventing heart attack and stroke. Levels are influenced by diet, exercise, body weight, thyroid function, and genetics, and respond strongly to statins and other lipid therapies.
Units: mg/dL; some labs report mmol/L (mmol/L = mg/dL × 0.0259). Check the units on your report before comparing to any range here.
Optimal range: who says what
Institutions, researchers and practitioners draw the line in different places. Each position is listed with who holds it and, where a document states it, a link. How we verify ranges.
- Institution or study≥70 mg/dL on a statin prompts add-on therapy in very high-risk ASCVD2018 AHA/ACC cholesterol guidelineSets treatment thresholds rather than an optimal level; LDL-C of 190 mg/dL or more is treated without calculating risk
- Institution or study<55 mg/dL very high risk; <70 high risk2019 ESC/EAS dyslipidaemia guidelinesEuropean targets run tighter than the US guideline at equal risk
- Institution or study<100 mg/dL optimal; 100-129 near or above optimalNCEP ATP III (NHLBI, 2001)ATP III classes 130-159 as borderline high, 160-189 high and 190 or more very high
- Institution or study50-70 mg/dLO'Keefe, Cordain et al. 2004 review (J Am Coll Cardiol)Based on LDL levels in hunter-gatherers, healthy neonates and wild primates, and on trials in which events were fewest when LDL was lowered below 70 mg/dL
- Named practitioner50-70 mg/dLDr. Michael Greger · Optimal Cholesterol Level
- Named practitioner80-100 mg/dL good / 40-80 betterLife Extension · Lab Testing Protocol (Suggested Optimal Ranges)Disclosure: Life Extension sells lab panels that appear in our blood-test comparisons.
- Named practitioner<70 mg/dLTracey O'Shea (Kresser Institute) · The Lipid Panel Was Fine. The Patient Was Not: A Case in Advanced Cardiovascular Risk Assessment
- Lab reference intervalLab classification (NCEP ATP III): Optimal <100 mg/dL, Near optimal 100-129 mg/dL, Borderline high 130-159 mg/dL, High 160-189 mg/dL, Very high ≥190 mg/dLWhat a lab report flags against. A lab interval is not an optimal target.
Practitioner targets are individual positions, often tighter than guideline ranges. Each was checked against its article before publishing.
21 of 21 itemized panels
Lipid Panel / Cardiovascular Health
What is LDL Cholesterol?
LDL Cholesterol (Low-Density Lipoprotein Cholesterol) is often called "bad cholesterol" because elevated levels drive atherosclerosis—the buildup of cholesterol plaques in arteries causing heart attacks and strokes. LDL particles transport cholesterol from the liver to peripheral tissues. When LDL levels are excessive, cholesterol infiltrates artery walls, triggering inflammation and plaque formation.
LDL cholesterol is either directly measured or calculated using the Friedewald equation: LDL = Total Cholesterol - HDL - (Triglycerides/5). This calculation is inaccurate when triglycerides >400 mg/dL, requiring direct LDL measurement. Modern guidelines emphasize that LDL reduction is the primary target of lipid-lowering therapy—each 40 mg/dL reduction in LDL decreases cardiovascular events by ~20%.
While LDL-C (cholesterol content) is widely used, it has limitations. Two people with identical LDL-C can have different numbers of LDL particles. Someone with many small dense LDL particles (Pattern B) has higher cardiovascular risk than someone with fewer large buoyant particles (Pattern A) despite the same LDL-C. This is why advanced testing (ApoB, LDL particle number) provides superior risk assessment, especially when triglycerides are elevated.
Why LDL Is the Primary Target for Cardiovascular Prevention
- Causal role in atherosclerosis: LDL drives plaque formation. Lifelong elevated LDL causes heart disease; lowering LDL prevents it
- Modifiable risk factor: Unlike age or genetics, LDL can be reduced 50-60% with medications, preventing most cardiovascular events
- Dose-response relationship: "Lower is better"—each 40 mg/dL reduction reduces cardiovascular risk 20-25%. No threshold below which benefit stops
- Treatment targets: LDL <100 mg/dL for moderate risk, <70 for high risk, <55 for very high risk (post-MI, stroke)
- Familial hypercholesterolemia: LDL >190 mg/dL suggests genetic disorder requiring lifelong aggressive treatment
- Superior to total cholesterol: LDL more accurately predicts cardiovascular risk than total cholesterol
Interpretation bands (curated, PMID-backed)
Holder: OptimizeBiomarkers editorial synthesis of: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines (Grundy et al., 2019); Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis (Navarese et al., 2018); Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis (Khan et al., 2022). No single paper sets these cutoffs; for attributed targets see who says what.
Optimal (Longevity)<70 mg/dL▼
- Associated with lowest cardiovascular risk
- Population studies show LDL <70 mg/dL dramatically reduces atherosclerosis progression
- Infants have LDL 30-70 mg/dL—likely our evolutionary baseline
- Modern guidelines recommend <70 mg/dL for secondary prevention, <55 mg/dL for very high risk
Near Optimal70-100 mg/dL▼
- Acceptable for primary prevention in low-risk individuals
- However, even this range causes gradual plaque accumulation over decades
- Consider targeting <70 mg/dL if family history, diabetes, or other risk factors present
Borderline to Moderately High100-189 mg/dL▼
- 100-129 (Borderline): Lifestyle modification essential
- Consider statin if diabetes or 10-year risk >7.5%
- 130-159 (Moderately High): Statin therapy indicated if diabetes, known heart disease, or multiple risk factors
- 160-189 (High): Statin strongly recommended
- If no contraindication, start moderate to high-intensity statin
Very High (Likely Familial Hypercholesterolemia)≥190 mg/dL▼
- Very high cardiovascular risk
- Strongly suggests familial hypercholesterolemia (FH), especially if <40 years old or family history of early heart disease
- Requires high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg)
- If LDL not <100 mg/dL on maximum statin, add ezetimibe 10 mg
- If still not at goal, add PCSK9 inhibitor
- Untreated FH causes heart attacks by age 50
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
- Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
- Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis.
What raises or lowers LDL Cholesterol
Causes of high LDL Cholesterol
High LDL causes:
- Diet: High saturated fat, trans fats, dietary cholesterol (eggs, shellfish - modest effect)
- Obesity: Especially abdominal/visceral fat
- Sedentary lifestyle: Physical inactivity worsens lipid profile
- Genetics: Familial hypercholesterolemia (LDL receptor defects), familial combined hyperlipidemia, familial defective ApoB
- Secondary causes: Hypothyroidism (check TSH), nephrotic syndrome (check urinalysis), cholestatic liver disease, diabetes (poor control)
- Medications: Thiazide diuretics, beta-blockers, cyclosporine, tacrolimus, protease inhibitors, anabolic steroids
- Age and gender: LDL rises with age. Women have lower LDL premenopause; rises after menopause
Causes of low LDL Cholesterol
Low LDL (<70 mg/dL without medication) causes:
- Malnutrition or malabsorption
- Hyperthyroidism (increased LDL catabolism)
- Severe liver disease (reduced synthesis)
- Genetic: Familial hypobetalipoproteinemia (very rare, generally benign)
- Very low LDL (<30 mg/dL) may rarely be associated with increased hemorrhagic stroke risk, though causality unclear
Symptoms when LDL Cholesterol is high or low
When high
Very high LDL (>190 mg/dL, especially FH) may cause visible signs:
- Tendon xanthomas: Cholesterol bumps on Achilles tendon, knuckles, elbows
- Xanthelasma: Yellow plaques on eyelids
- Corneal arcus: Gray-white ring around cornea (if age <45)
- Family history: Relatives with early heart disease (<55 men, <65 women)
Most people with high LDL have no physical signs. Xanthomas suggest LDL >300 mg/dL or familial hypercholesterolemia.
When low
High LDL causes no symptoms until complications occur:
- Angina: Chest pain from coronary artery disease. Often first symptom of decades of high LDL
- Heart attack: Myocardial infarction from plaque rupture. May be first manifestation
- Stroke: From carotid artery atherosclerosis
- Peripheral artery disease: Leg pain with walking (claudication)
- Xanthomas: Cholesterol deposits in tendons (if LDL >190 mg/dL, especially FH)
High LDL is asymptomatic for decades while silently damaging arteries. Symptoms only appear when atherosclerosis is advanced. This is why early screening and prevention are critical.
How to move LDL Cholesterol
Effect sizes (how much something moves the marker) appear only where the paper cited under the item states them. Talk to your clinician before starting or changing any medication or supplement.
Dietary Interventions for LDL Reduction
- Reduce saturated fat: Limit to <7% of calories. Replacing it with unsaturated fat lowers LDL. Major sources: red meat, butter, cheese, palm/coconut oil
- Eliminate trans fats: Avoid partially hydrogenated oils. Trans fats raise LDL and lower HDL
- Plant-based diet: Vegan and vegetarian diets lower LDL. Emphasize legumes, whole grains, vegetables, fruits
- Soluble fiber: 10-25g daily. Oats, barley, psyllium, beans, apples. Soluble fiber lowers LDL modestly
- Plant sterols/stanols: 2g daily from fortified foods or supplements. They block cholesterol absorption; in a meta-analysis of randomised trials, 0.6-3.3 g daily lowered LDL cholesterol by 6-12% on average (Ras 2014)
- Portfolio diet: Combines plant sterols, viscous fiber, soy protein, almonds. Combining these foods lowers LDL more than any one of them
Statin Therapy - First Line Treatment
- Moderate-intensity statins: Atorvastatin 10-20 mg or rosuvastatin 5-10 mg. Lower LDL substantially
- High-intensity statins: Atorvastatin 40-80 mg or rosuvastatin 20-40 mg. The 2018 AHA/ACC cholesterol guideline uses a maximally tolerated statin to lower LDL-C by 50% or more (Grundy 2018)
- Primary prevention indications: LDL ≥190 mg/dL (any age), diabetes age 40-75, 10-year ASCVD risk ≥7.5%
- Secondary prevention: All patients with heart disease, stroke, PAD require high-intensity statin regardless of LDL level
- Monitoring: Check LDL 4-12 weeks after starting. The 2019 ESC/EAS guidelines target <70 mg/dL at high risk and <55 at very high risk; NCEP ATP III calls <100 optimal
- Side effects: Muscle aches are the most common complaint. Try different statin, alternate-day dosing, or CoQ10 100-200 mg daily
Additional LDL-Lowering Medications
- Ezetimibe: 10 mg daily. Blocks intestinal cholesterol absorption. Lowers LDL further on top of a statin. Add to statin if not at goal. IMPROVE-IT trial showed cardiovascular benefit
- PCSK9 inhibitors: Evolocumab or alirocumab subcutaneous injection every 2-4 weeks. In the FOURIER trial, evolocumab added to a statin lowered LDL cholesterol by 59% (Sabatine 2017). For FH, statin-intolerant, or LDL not at goal on max therapy. Expensive but highly effective
- Bempedoic acid: 180 mg daily. Inhibits cholesterol synthesis upstream of statins. Lowers LDL moderately. For statin-intolerant patients
- Inclisiran: SiRNA injection every 6 months. Lowers LDL by silencing the PCSK9 gene. Convenient dosing
- Bile acid sequestrants: Cholestyramine, colesevelam. Lower LDL moderately, but GI side effects limit use
Source: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Lifestyle Modifications
- Weight loss: Losing excess weight lowers LDL
- Aerobic exercise: 150-300 min/week moderate intensity. Lowers LDL modestly but improves particle size and reduces small dense LDL
- Smoking cessation: Smoking oxidizes LDL, making it more atherogenic. Quitting improves LDL quality even if level unchanged
- Limit alcohol: Heavy drinking raises LDL. Limit to ≤1-2 drinks daily
- Stress management: Chronic stress increases LDL via cortisol. Meditation, adequate sleep (7-9 hours) help
- Intermittent fasting: Time-restricted eating or alternate-day fasting may lower LDL slightly
Advanced Lipid Testing and Aggressive Targets
- ApoB measurement: More accurate than LDL-C for risk assessment. Each LDL particle has one ApoB. The ApoB page lists who sets which target
- LDL particle number (LDL-P): If triglycerides elevated, LDL-P may be high despite "normal" LDL-C (discordance). The LDL particle number page lists who sets which target
- Non-HDL cholesterol: Total - HDL = non-HDL. Captures LDL + VLDL + remnants. NCEP ATP III sets the non-HDL goal 30 mg/dL above the LDL-C goal
- CAC score: Coronary artery calcium quantifies atherosclerosis. The 2018 AHA/ACC guideline treats a CAC score of 100 or more as favoring statin therapy
- Lower is better: Recent trials (FOURIER, ODYSSEY) showed further benefit at very low LDL levels, with no lower threshold identified
When to retest
- Screening: Age 20-39 every 5 years, age 40+ every 1-2 years. More frequent if borderline or on therapy
- After lifestyle changes: Retest in 6-12 weeks. Diet and exercise can lower LDL
- After starting/changing statin: Retest in 4-12 weeks. Adjust dose to achieve LDL goal
- On stable therapy: Check annually for adherence and monitoring. If not at goal, intensify therapy
- Post-cardiovascular event: Check 24-48 hours after heart attack (acute drop occurs), then 4-6 weeks later on therapy
- Familial hypercholesterolemia: Screen children at age 2 if parent has FH. Otherwise screen all children 9-11 and 17-21
- Treatment targets: The 2019 ESC/EAS guidelines set <70 mg/dL at high risk and <55 at very high risk; NCEP ATP III calls <100 optimal (see who says what above)
Scientific Evidence
LDL Causes Atherosclerosis
A European Atherosclerosis Society panel reviewed genetic studies, over 200 cohort studies, Mendelian randomization studies and randomized trials covering more than 2 million participants. It found a consistent dose-dependent link between LDL exposure and cardiovascular disease that grows with the duration of exposure, and concluded that LDL causes atherosclerotic cardiovascular disease.
Statins Work in Women and Men
In 27 trials with 174,149 participants, statins reduced major vascular events per 1.0 mmol/L LDL reduction similarly in women (RR 0.84) and men (RR 0.78), and reduced all-cause mortality in both.
PCSK9 Inhibitor Trial
In 27,564 patients with cardiovascular disease on statins, evolocumab lowered LDL from a median of 92 to 30 mg/dL and reduced the primary endpoint (9.8% vs 11.3%; HR 0.85) over 2.2 years, with no excess adverse events apart from injection-site reactions.
Source: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Which Providers Test LDL Cholesterol?
Cheapest: Oura Health Panels at $99/year. Most comprehensive: Function Health, 160+ biomarkers for $365/year.
21 panels that include it, cheapest first
| Provider | Annual Cost | Total Biomarkers | $/Biomarker |
|---|---|---|---|
| $99 | 50 | $1.98 | |
| $190 | 100+ | $1.90 | |
| $250 | 65 | $3.85 | |
| $297 | 100+ | $2.97 | |
 Labcorp OnDemand | $338 | 50+ | $6.76 |
 Superpower | $349 | 100+ | $3.49 |
| $349 | 75+ | $4.65 | |
 WHOOP Advanced Labs | $349 | 65 | $5.37 |
 Function Health | $365 | 160+ | $2.28 |
| $365 | 100+ | $3.65 | |
| $375 | 108 | $3.47 | |
| $449 | 83 | $5.41 | |
| $495 | 80+ | $6.19 | |
| $499 | 100+ | $4.99 | |
| $700 | 138 | $5.07 | |
| $829 | 54 | $15.35 | |
| $895 | 100+ | $8.95 | |
| $996 | 59 | $16.88 | |
| $1188 | 70+ | $16.97 | |
| $1198 | 40+ | $29.95 | |
| $1950 | 130+ | $15.00 |
$/Biomarker is annual cost divided by the panel's advertised biomarker count, not the price of this one test. We track 23 blood test providers (32 plans); 21 of those plans are itemized marker by marker. Compare all of them.
11 providers not itemized in our matrix
We have not itemized these marker by marker (some sell tests one at a time), so this page cannot say whether they offer LDL Cholesterol. Check with them directly.
Life Extension Standard · Quest Health · Ultrahuman Blood Vision · Lifeforce · Hundred Health · Personalabs · Walk-In Lab · HealthLabs · WHOOP Specialized Panels · Marek Health Essential · Vitality Blueprint Upload
Experts discussing LDL Cholesterol
Podcast episodes where clinicians and researchers cover this marker in depth. Curated by hand; an episode is listed only when the marker is a substantial topic, not a passing mention.
- Does omega-3 reduce cardiovascular disease? Comparing major trials
- Episode 171: July 2022 Bloodwork Review
- Sky High LDL on Keto/Carnivore: Should You Worry?
- When You Should Worry About LDL Cholesterol
- Episode 385: Carnivore Diet and Dr. Baker's Blood Work
- Bryan Johnson's Blueprint: The 11 Biomarkers for LongevityDisclosure: This is Bryan Johnson's podcast; Johnson owns Blueprint, which appears in our blood-test comparisons.
Frequently Asked Questions
What is the optimal range for LDL Cholesterol?
Published positions differ: ≥70 mg/dL on a statin prompts add-on therapy in very high-risk ASCVD (2018 AHA/ACC cholesterol guideline); <55 mg/dL very high risk; <70 high risk (2019 ESC/EAS dyslipidaemia guidelines); <100 mg/dL optimal; 100-129 near or above optimal (NCEP ATP III (NHLBI, 2001)); 50-70 mg/dL (O'Keefe, Cordain et al. 2004 review (J Am Coll Cardiol)). Named practitioners target: 50-70 mg/dL (Dr. Michael Greger); 80-100 mg/dL good / 40-80 better (Life Extension); <70 mg/dL (Tracey O'Shea (Kresser Institute)). Lab classification (NCEP ATP III): Optimal <100 mg/dL, Near optimal 100-129 mg/dL, Borderline high 130-159 mg/dL, High 160-189 mg/dL, Very high ≥190 mg/dL.
Which blood test providers include LDL Cholesterol?
21 of the 21 blood testing panels we itemize marker by marker include LDL Cholesterol in their panels. This biomarker is widely available across major providers.
Related: YouBoost rates lifestyle and supplement interventions by evidence; HRV Zone tracks recovery trends.
Medical Disclaimer
This information is for educational purposes only and is not medical advice. Always consult with a qualified healthcare provider about your specific health needs.
Last reviewed Sep 23, 2026 · First published Sep 30, 2025